KBC Group’s Zymeworks ZYME Stock Holding History

KBC Group’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-85	Closed	-$2K	–	1554
2019 Q3	$2K	Buy	+85	New	+$2.13K	﹤0.01%	1472

Other funds holding ZYME

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KBC Group's ZYME Position: Q4 2019 in Review

KBC Group sold out of Zymeworks (ZYME) in Q4 2019, closing a stake of 85 shares — an estimated $2K sold.

KBC Group first reported a position in ZYME in Q3 2019 and held it in 1 quarter. The position peaked at $2K in Q3 2019. 103 funds tracked by Wall St. Rank hold ZYME as of Q4 2019.

KBC Group reported no remaining Zymeworks position as of Q4 2019 after selling out during the quarter.
KBC Group sold 85 Zymeworks shares in Q4 2019, an estimated $2K.
KBC Group first reported a position in Zymeworks in Q3 2019 and held it in 1 quarter.
KBC Group's Zymeworks position peaked at $2K in Q3 2019.
103 funds tracked by Wall St. Rank held Zymeworks as of Q4 2019.

Based on KBC Group's 13F filing for Q4 2019, filed 11 Feb 2020.